329 related articles for article (PubMed ID: 27236577)
1. Bone marrow niche in immune thrombocytopenia: a focus on megakaryopoiesis.
Khodadi E; Asnafi AA; Shahrabi S; Shahjahani M; Saki N
Ann Hematol; 2016 Oct; 95(11):1765-76. PubMed ID: 27236577
[TBL] [Abstract][Full Text] [Related]
2. Dysregulated megakaryocyte distribution associated with nestin
Wang M; Feng R; Zhang JM; Xu LL; Feng FE; Wang CC; Wang QM; Zhu XL; He Y; Xue J; Fu HX; Lv M; Kong Y; Chang YJ; Xu LP; Liu KY; Huang XJ; Zhang XH
Blood Adv; 2019 May; 3(9):1416-1428. PubMed ID: 31053569
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of hypoxia-inducible factor-1α contributes to impaired megakaryopoiesis in immune thrombocytopenia.
Qi J; You T; Pan T; Wang Q; Zhu L; Han Y
Thromb Haemost; 2017 Oct; 117(10):1875-1886. PubMed ID: 28771276
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study on bone marrow megakaryocytes in children with thrombocytopenic purpura, aplastic anemia and myelodysplastic syndrome].
Hu T; Shi XD; Feng YL; Liu R; Li JH; Chen J; Wang TY
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):183-7. PubMed ID: 15833188
[TBL] [Abstract][Full Text] [Related]
5. Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice.
Barbieri SS; Petrucci G; Tarantino E; Amadio P; Rocca B; Pesce M; Machlus KR; Ranelletti FO; Gianellini S; Weksler B; Italiano JE; Tremoli E
Thromb Haemost; 2015 Nov; 114(6):1218-29. PubMed ID: 26272103
[TBL] [Abstract][Full Text] [Related]
6. Decreased cyclooxygenase-2 associated with impaired megakaryopoiesis and thrombopoiesis in primary immune thrombocytopenia.
Zhuang X; Xu P; Ou Y; Shao X; Li Y; Ma Y; Qin S; Hua F; Zhan Y; Ji L; Qiao T; Chen H; Cheng Y
J Transl Med; 2023 Aug; 21(1):540. PubMed ID: 37573325
[TBL] [Abstract][Full Text] [Related]
7. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura.
Gernsheimer TB
Hematology Am Soc Hematol Educ Program; 2008; ():219-26. PubMed ID: 19074086
[TBL] [Abstract][Full Text] [Related]
8. Decreased Expression of IL-35 and Its Receptor Contributes to Impaired Megakaryopoiesis in the Pathogenesis of Immune Thrombocytopenia.
Cai X; Gui RY; Wu J; Wang CC; Zhu XL; Fu HX; Zhang XH
Adv Sci (Weinh); 2024 Mar; 11(12):e2305798. PubMed ID: 38225757
[TBL] [Abstract][Full Text] [Related]
9. The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia.
Zhang D; Li H; Ma L; Zhang X; Xue F; Zhou Z; Chi Y; Liu X; Huang Y; Yang Y; Yang R
Autoimmunity; 2014 Dec; 47(8):519-29. PubMed ID: 25019270
[TBL] [Abstract][Full Text] [Related]
10. Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression.
Zhang JM; Feng FE; Wang QM; Zhu XL; Fu HX; Xu LP; Liu KY; Huang XJ; Zhang XH
Stem Cells Transl Med; 2016 Dec; 5(12):1631-1643. PubMed ID: 27471307
[TBL] [Abstract][Full Text] [Related]
11. Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production.
Abraham M; Weiss ID; Wald H; Wald O; Nagler A; Beider K; Eizenberg O; Peled A
Br J Haematol; 2013 Oct; 163(2):248-59. PubMed ID: 23906028
[TBL] [Abstract][Full Text] [Related]
12. [Megakaryocyte development and platelet production in normal and disease states].
Deutsch V; Katz BZ; Tomer A
Harefuah; 2010 May; 149(5):291-7, 336. PubMed ID: 20929068
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow niche-inspired, multiphase expansion of megakaryocytic progenitors with high polyploidization potential.
Panuganti S; Papoutsakis ET; Miller WM
Cytotherapy; 2010 Oct; 12(6):767-82. PubMed ID: 20482285
[TBL] [Abstract][Full Text] [Related]
14. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.
Deutsch VR; Tomer A
Br J Haematol; 2013 Jun; 161(6):778-93. PubMed ID: 23594368
[TBL] [Abstract][Full Text] [Related]
15. Megakaryocyte apoptosis in immune thrombocytopenia.
Vrbensky JR; Nazy I; Toltl LJ; Ross C; Ivetic N; Smith JW; Kelton JG; Arnold DM
Platelets; 2018 Nov; 29(7):729-732. PubMed ID: 29787328
[TBL] [Abstract][Full Text] [Related]
16. Deciphering transcriptome alterations in bone marrow hematopoiesis at single-cell resolution in immune thrombocytopenia.
Liu Y; Zuo X; Chen P; Hu X; Sheng Z; Liu A; Liu Q; Leng S; Zhang X; Li X; Wang L; Feng Q; Li C; Hou M; Chu C; Ma S; Wang S; Peng J
Signal Transduct Target Ther; 2022 Oct; 7(1):347. PubMed ID: 36202780
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF-κB/SMAD pathway in patients with immune thrombocytopenia.
He Y; Xu LL; Feng FE; Wang QM; Zhu XL; Wang CC; Zhang JM; Fu HX; Xu LP; Liu KY; Huang XJ; Zhang XH
Br J Haematol; 2018 Feb; 180(3):395-411. PubMed ID: 29327472
[TBL] [Abstract][Full Text] [Related]
18. Blood platelet production and morphology.
Malara A; Balduini A
Thromb Res; 2012 Mar; 129(3):241-4. PubMed ID: 22226434
[TBL] [Abstract][Full Text] [Related]
19. GSK-3β negatively regulates megakaryocyte differentiation and platelet production from primary human bone marrow cells in vitro.
Ono M; Matsubara Y; Shibano T; Ikeda Y; Murata M
Platelets; 2011; 22(3):196-203. PubMed ID: 21231855
[TBL] [Abstract][Full Text] [Related]
20. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
